ACTIVE STUDIES RECRUITING:

• J4Z-MC-GIDI – Obesity and Overweight/ Type 2 Diabetes

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J1I-MC-GZQA (TRANSCEND-T2D-3) – Kidney Disease / Type 2 Diabetes / Insulin

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• W8M-MC-CWMM – Overweight and Obesity / With or without Type 2 Diabetes

A phase 2 Trial with the main purpose to investigate the effect of LY3305677 Compared with Placebo in Adult Participants with Obesity or Overweight with or without Diabetes. The study will last around 65 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• NN1436-8182 (ONWARDS 11) – Type 1 Diabetes

A trial investigating the effect and safety of once-weekly insulin icodec in combination with insulin aspart, using an updated titration algorithm, in comparison to once-daily insulin glargine in combination with insulin aspart, in multiple daily injection treated adults with T1D. The study will last around 8 months.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

ACTIVE STUDIES NON-RECRUITING:

• NN9388-4894 (REIMAGINE 4) –Overweight and Obesity/T2DM

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight and their blood sugar. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. Duration of the Trial is around 1.5 years.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• NN9388-4896 (REIMAGINE 2) – T2DM/Overweight and Obesity

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. Duration of the Trial is around 1.5 years.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J2A-MC- GZGS – T2DM/Overweight/Obesity

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J1I-MC-GZBU – T2DM/Kidney Disease/Overweight and Obesity

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

COMPLETED STUDIES:

  • Afimmune – DS102A-07-CV1 – T2DM/ Hypertriglyceridemia – 2022

  • Andromeda Biotech Ltd. – DiaPep277-1001 – T1DM – 2014

  • Anji Pharma – ANJ900D3501 – T2DM – 2023

  • AstraZeneca – D9183C0001 – DKD – 2023

  • Bayer – 17530 (FIGARO) – DKD – 2021

  • Boehringer Ingelheim – 1218.89 (MARLINA) – T2DM – 2016

  • Boehringer Ingelheim – 1218.22 (CARMELINA) – T2DM – 2018

  • CSL Behring – CSL346_2001 (MANEUVER) – DKD – 2022

  • Eli Lilly and Co. – H9X-MC-GBDX – T2DM / CKD – 2016

  • Eli Lilly and Co. – I8B-MC-ITSW – T2DM – 2022

  • Eli Lilly and Co. – J1I-MC-GZBD – T2DM – 2022

  • Eli Lilly and Co. – I8F-MC-GPHL (SURMOUNT 2) – T2DM/ Overweight/Obesity – 2023

  • GlaxoSmithKline – GSK-200952 – T2DM -2017

  • Ironwood Pharmaceuticals – C1973-203 – T2DM w/ Diabetic Nephropathy – 2019

  • Janssen Research & Development, LLC – 28431754DIA2004 – T1DM – 2015

  • Janssen Research & Development, LLC – 28431754DNE3001 (CREDENCE) – T2DM/Diabetic Nephropathy – 2018

  • Lexicon Pharmaceuticals – LX4211.1.309 – T1DM – 2014

  • Lexicon Pharmaceuticals – EFC14834 – T2DM – 2019

  • Lexicon Pharmaceuticals – EFC14868 (SOTA-INS) – T2DM – 2019

  • Merck Sharp & Dohme LLC – MK-0431D-266 – T2DM -2013

  • Merck Sharp & Dohme LLC – MK-3102_027 – T2DM – 2014

  • Merck Sharp & Dohme LLC – MK-3102-016 – T2DM – 2015

  • Merck Sharp & Dohme LLC – MK-3102-019 -T2DM – 2016

  • Merck Sharp & Dohme LLC – MK-3102-018 – T2DM – 2017

  • Merck Sharp & Dohme LLC – MK-8835-004 B1521021 – T2Dm – 2020

  • Mylan Inc. – MYL-1501D-3004 – T1DM – 2019

  • Mylan Inc. – MYL-1601D-3001 (GAZELLE) – T1DM – 2020

  • Novo Nordisk – EX9536-4388 (select) – Overweight/Obesity – 2023

  • Novo Nordisk – NN1218-3852 – T1DM – 2015

  • Novo Nordisk – NN2211-4059 (LIRA SWITCH) – T2DM – 2015

  • Novo Nordisk – NN1250-3995 (SWITCH 1) – T1DM – 2016

  • Novo Nordisk – NN9828-4150 – T1DM – 2019

  • Novo Nordisk – NN1535-4593 (COMBINE 3) – T2DM

  • Novo Nordisk – NN1436-4478 (ONWARDS 2) – T2DM – 2022

  • Novo Nordisk – NN1436-4625 (ONWARDS 6) – T1DM – 2022

  • Novo Nordisk – NN9838-4862 – T2DM – 2022

  • Sanofi – DRI13940 – T2DM – 2017

  • Sanofi – LPS14347 – T2DM – 2018

  • Sanofi – EFC15081 (GEMELLI 1) – T1DM/T2DM – 2019

  • Sanofi – EFC15178 (GEMELLI X) – T1DM – 2020

  • Teijin America Inc. – TMX-049DN-201 – DKD – 2019

  • COVALENT-112 – Type 1 Diabetes
  • J2A-MC-GZGT- T2DM/Overweight And Obesity
  • 901-C-2102 (CYPRESS Trial) – Diabetic Neuropathy
  • I8H-MC-BDCW – T2DM
  • NN9536-7545 (STEP-UP)- T2DM/Overweight/Obesity
  • NN9838-4609 (REDEFINE 2) – T2DM/ Overweight/Obesity
  • NN1535-4591 (COMBINE 1) – T2DM

info@PlanItResearch.com